HER2 Support Group Forums - View Single Post - statistics for efficacy of adding herceptin to chemo for small, node-negative her2+bc

Lani · 12-13-2011, 10:35 AM

the following is a great article on how many/few would have in all l likelihood achieved a PCR if their tumor had been big enough when found to do neoadjuvant treatment, depending on how ER+ it was... it assumes the behavior of her2+ breast cancer is the same once it has become invasive whether it is found at T1 stage or T2 and greater stage (you may or may not want to make this assumption, but it certainly fits better for her2 than for quite a few other types of bc):

Modern Pathology advance online publication 19 November 2010; doi: 10.1038/modpathol.2010.209
Semiquantitative hormone receptor level influences response to
trastuzumab-containing neoadjuvant chemotherapy in HER2-
positive breast cancer
Rohit Bhargava1, David J Dabbs1, Sushil Beriwal2, Isil A Yildiz1, Preeti Badve1, Atilla Soran3,
Ronald R Johnson3, Adam M Brufsky4, Barry C Lembersky4, Kandace P McGuire3 and Gretchen
M Ahrendt3

It discusses treatment with chemo with and without herceptin.
Adjuvant studies where they give herceptin first, rebiopsy, then addd chemo might also give an idea of how much difference the chemo makes, but they have not usually been graded as well as this one as to HOW ER+ the tumor was.

12-13-2011, 10:35 AM	#6
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Re: statistics for efficacy of adding herceptin to chemo for small, node-negative her the following is a great article on how many/few would have in all l likelihood achieved a PCR if their tumor had been big enough when found to do neoadjuvant treatment, depending on how ER+ it was... it assumes the behavior of her2+ breast cancer is the same once it has become invasive whether it is found at T1 stage or T2 and greater stage (you may or may not want to make this assumption, but it certainly fits better for her2 than for quite a few other types of bc): Modern Pathology advance online publication 19 November 2010; doi: 10.1038/modpathol.2010.209 Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2- positive breast cancer Rohit Bhargava1, David J Dabbs1, Sushil Beriwal2, Isil A Yildiz1, Preeti Badve1, Atilla Soran3, Ronald R Johnson3, Adam M Brufsky4, Barry C Lembersky4, Kandace P McGuire3 and Gretchen M Ahrendt3 It discusses treatment with chemo with and without herceptin. Adjuvant studies where they give herceptin first, rebiopsy, then addd chemo might also give an idea of how much difference the chemo makes, but they have not usually been graded as well as this one as to HOW ER+ the tumor was.